#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Immune-mediated renal disorder Leukocyte adhesion deficiency type I Astrocytoma Primary hyperoxaluria Small intestine neuroendocrine tumour Mantle cell lymphoma stage II Duchenne muscular dystrophy gene carrier Myeloproliferative neoplasm X-linked lymphoproliferative syndrome Necrotising enterocolitis neonatal Sickle cell anaemia Myelin oligodendrocyte glycoprotein antibody-associated disease Endometrial cancer Hereditary spastic paraplegia Pneumonia More trials…

    Learn about Rare Diseases

    Focal segmental glomerulosclerosis Usher’s syndrome – Trials in Disease Pulmonary sarcoidosis – Diagnostics Pelizaeus-Merzbacher disease – Basic Information Krabbe’s disease Hepatoblastoma – Basic Information Krabbe’s disease – Basic Information Nephroblastoma – Life with Disease Nephroblastoma – Trials in Disease Pleomorphic leiomyosarcoma More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Avatrombopag Upadacitinib Triptorelin Pamoate Ambrisentan Temocillin Nicotinamide Botaretigene Sparoparvovec Gadoteric Acid Ecoo1A Cusatuzumab Meropenem Ferrous Sulfate Secukinumab Mepolizumab Pentixafor Calcium Chloride Povidone, Iodinated Proline Metoprolol Succinate Lsta1 More therapies…

    Learn about Your Condition

    Cervix carcinoma Thrombocytosis Hypopituitarism Endocrine ophthalmopathy Fracture infection Giardiasis Arterial disorder Relapsing multiple sclerosis Keratosis follicular Right ventricular dysfunction Laparoscopic surgery Polycystic ovarian syndrome Haemorrhage Crohn's disease Eosinophilic oesophagitis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Bacs-Kiskun Varmegyei Oktatokorhaz

Bacs-Kiskun Varmegyei Oktatokorhaz

Nyiri Ut 38, Kecskemet, 6000, Hungary

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Datopotamab Deruxtecan and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with Low PD-L1 Levels

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Datopotamab Deruxtecan
    Austria Belgium Czechia France Germany Greece +7

  • Study Comparing Subcutaneous Pembrolizumab with Hyaluronidase to Intravenous Pembrolizumab and Chemotherapy for First-line Treatment of Metastatic Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Glatiramer Acetate
    • Carboplatin
    • Cisplatin
    France Hungary Poland Romania Spain

  • Study on Vericiguat for Adults with Chronic Heart Failure with Reduced Ejection Fraction

    Not recruiting

    3 1
    Investigated Diseases:
    • Heart failure with reduced ejection fraction
    Investigated Drugs:
    • Vericiguat
    Austria Czechia Denmark France Germany Greece +6

  • Study on Trilaciclib and Topotecan for Patients with Extensive Stage Small Cell Lung Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Small cell lung cancer extensive stage
    Investigated Drugs:
    • Trilaciclib Dihydrochloride Dihydrate
    • Glucose Monohydrate
    • Sodium Chloride
    Austria Belgium Bulgaria Germany Greece Hungary +2

  • Study of Pembrolizumab with Chemoradiotherapy for Patients with Muscle-Invasive Bladder Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Mitomycin
    • Cisplatin
    • Fluorouracil
    Czechia Estonia France Hungary Italy Latvia +5

  • Study of Pembrolizumab as Additional Treatment for Patients with Liver Cancer (Hepatocellular Carcinoma) After Surgery or Local Ablation

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Pembrolizumab
    Belgium Denmark France Germany Hungary Ireland +5

  • Study on Milvexian and Drug Combination for Patients Recovering from a Heart Attack

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Acetylsalicylic Acid
    • Clopidogrel
    • Milvexian
    Austria Belgium Bulgaria Croatia Czechia Denmark +14

  • Study on Milvexian and Apixaban for Preventing Stroke in Patients with Atrial Fibrillation

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Atrial fibrillation
    Investigated Drugs:
    • Andexanet Alfa
    • Apixaban
    • Milvexian
    Belgium Bulgaria Croatia Czechia Denmark Estonia +13

  • Study of RO7247669 and Nab-Paclitaxel vs. Pembrolizumab and Nab-Paclitaxel for Patients with Untreated, PD-L1 Positive, Advanced Triple-Negative Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Czechia Denmark Germany Hungary Italy The Netherlands +2

  • Study Comparing Sacituzumab Govitecan with Other Treatments for Patients with HR+/HER2- Metastatic Breast Cancer After Endocrine Therapy

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Antiemetics And Antinauseants
    • Antipsychotics
    • Capecitabine
    Austria Belgium Czechia France Germany Greece +5
Previous Page
1 … 10 11 12 13
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!